Nghe An officials meeting with the SK Group delegation to discuss the proposed investment. Photo: Nghe An province The Nghe An government held a working session with a delegation from SK Group, led by ...

Why did two private equity firms with more than $460 billion under management want a little old gene therapy biotech called ...

Capital One is tightening access to its exclusive airport lounges, no longer allowing all premium credit cardholders to extend free entry to additional cardholders and guests. Starting early next ...

SOMERVILLE, Mass., May 16, 2025--As previously announced on May 14, 2025, Carlyle (NASDAQ: CG) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird ...

Carlyle Media: Brittany Berliner (212) 813-4839 [email protected] SK Capital Ben Dillon (646)-278-1353 [email protected] Source: bluebird bio, Inc.

SK Capital’s portfolio of businesses generates revenues of approximately $12 billion annually, employs more than 25,000 people globally, and operates more than 200 plants in over 30 countries.

SK Capital’s portfolio of businesses generates revenues of approximately $12 billion annually, employs more than 25,000 people globally, and operates more than 200 plants in over 30 countries.

Carlyle and SK Capital Partners have agreed to pay $3 in cash for each share of Bluebird, the biotech announced Friday. That price is a 57% discount to the company’s closing stock price Thursday.